The biological underpinnings of therapeutic resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Beatty, Gregory L., Werba, Gregor, Lyssiotis, Costas A., Simeone, Diane M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247606/
https://www.ncbi.nlm.nih.gov/pubmed/34117095
http://dx.doi.org/10.1101/gad.348523.121
_version_ 1783716551891877888
author Beatty, Gregory L.
Werba, Gregor
Lyssiotis, Costas A.
Simeone, Diane M.
author_facet Beatty, Gregory L.
Werba, Gregor
Lyssiotis, Costas A.
Simeone, Diane M.
author_sort Beatty, Gregory L.
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this review, we discuss recent advances in our understanding of the biological underpinnings of PDAC and their implications as targetable vulnerabilities in this highly lethal disease.
format Online
Article
Text
id pubmed-8247606
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory Press
record_format MEDLINE/PubMed
spelling pubmed-82476062022-01-01 The biological underpinnings of therapeutic resistance in pancreatic cancer Beatty, Gregory L. Werba, Gregor Lyssiotis, Costas A. Simeone, Diane M. Genes Dev Review Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this review, we discuss recent advances in our understanding of the biological underpinnings of PDAC and their implications as targetable vulnerabilities in this highly lethal disease. Cold Spring Harbor Laboratory Press 2021-07-01 /pmc/articles/PMC8247606/ /pubmed/34117095 http://dx.doi.org/10.1101/gad.348523.121 Text en © 2021 Beatty et al.; Published by Cold Spring Harbor Laboratory Press https://creativecommons.org/licenses/by-nc/4.0/This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Beatty, Gregory L.
Werba, Gregor
Lyssiotis, Costas A.
Simeone, Diane M.
The biological underpinnings of therapeutic resistance in pancreatic cancer
title The biological underpinnings of therapeutic resistance in pancreatic cancer
title_full The biological underpinnings of therapeutic resistance in pancreatic cancer
title_fullStr The biological underpinnings of therapeutic resistance in pancreatic cancer
title_full_unstemmed The biological underpinnings of therapeutic resistance in pancreatic cancer
title_short The biological underpinnings of therapeutic resistance in pancreatic cancer
title_sort biological underpinnings of therapeutic resistance in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247606/
https://www.ncbi.nlm.nih.gov/pubmed/34117095
http://dx.doi.org/10.1101/gad.348523.121
work_keys_str_mv AT beattygregoryl thebiologicalunderpinningsoftherapeuticresistanceinpancreaticcancer
AT werbagregor thebiologicalunderpinningsoftherapeuticresistanceinpancreaticcancer
AT lyssiotiscostasa thebiologicalunderpinningsoftherapeuticresistanceinpancreaticcancer
AT simeonedianem thebiologicalunderpinningsoftherapeuticresistanceinpancreaticcancer
AT beattygregoryl biologicalunderpinningsoftherapeuticresistanceinpancreaticcancer
AT werbagregor biologicalunderpinningsoftherapeuticresistanceinpancreaticcancer
AT lyssiotiscostasa biologicalunderpinningsoftherapeuticresistanceinpancreaticcancer
AT simeonedianem biologicalunderpinningsoftherapeuticresistanceinpancreaticcancer

Ejemplares similares